LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4459 | 4168 | 1.0699 | 1.0881 |
| SK-BR-3 | NVP-TAE684 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 2443 | 4168 | 0.5857 | 0.4215 |
| MCF7 | Geldanamycin | 3.33 | uM | LJP5 | 72 | hr | 1209 | 1071 | 4203 | 0.2550 | -0.0661 |
| MCF7 | Geldanamycin | 3.33 | uM | LJP6 | 72 | hr | 1209 | 1126 | 4012 | 0.2806 | -0.0413 |
| MCF7 | TWS119 | 3.33 | uM | LJP5 | 72 | hr | 1209 | 2957 | 4203 | 0.7033 | 0.6432 |
| MCF7 | NU7441 | 3.33 | uM | LJP5 | 72 | hr | 1209 | 3054 | 4203 | 0.7274 | 0.6752 |
| MCF7 | WZ3105 | 3.33 | uM | LJP5 | 72 | hr | 1209 | 663 | 4203 | 0.1583 | -0.2842 |
| MCF7 | AZD 5438 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 669 | 4012 | 0.1664 | -0.2923 |
| MCF7 | HG-5-88-01 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 1982 | 4012 | 0.4938 | 0.3291 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 2431 | 4245 | 0.5729 | 0.4101 |
| MCF7 | PD173074 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 3926 | 4012 | 0.9796 | 0.9771 |
| MCF7 | OSI-027 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 1459 | 4012 | 0.3648 | 0.1153 |
| SK-BR-3 | WH-4-025 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 4040 | 4245 | 0.9601 | 0.9525 |
| MCF7 | YM 201636 | 3.33 | uM | LJP5 | 72 | hr | 1209 | 1757 | 4203 | 0.4190 | 0.2314 |
| MCF7 | SU11274 | 3.33 | uM | LJP5 | 72 | hr | 1209 | 3108 | 4203 | 0.7394 | 0.6899 |
| MCF7 | XL147 | 3.33 | uM | LJP5 | 72 | hr | 1209 | 4318 | 4203 | 1.0277 | 1.0308 |
| MCF7 | Y39983 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 3292 | 4012 | 0.8227 | 0.7870 |
| MCF7 | WYE-125132 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 1170 | 4012 | 0.2922 | -0.0187 |
| SK-BR-3 | A443654 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 984 | 4168 | 0.2361 | -0.2020 |
| MCF7 | Nintedanib | 3.33 | uM | LJP6 | 72 | hr | 1209 | 2411 | 4012 | 0.6011 | 0.4897 |
| MCF7 | AZD7762 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 993 | 4012 | 0.2477 | -0.1080 |
| MCF7 | Vemurafenib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 4259 | 4203 | 1.0147 | 1.0170 |
| MCF7 | Crizotinib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 1299 | 4203 | 0.3095 | 0.0403 |
| MDA-MB-231 | WYE-125132 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 1552 | 4405 | 0.3526 | 0.1324 |
| MDA-MB-231 | OSI-027 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 2665 | 4405 | 0.6061 | 0.5215 |